In 1604, Tanabeya Matazaemon is granted a license by Tokugawa Ieyasu for trade in herbal medicines with Luzon and Siam.[7]
In 1901, Motosaburo Tanabe, the Twelfth established a pharmacy in Tokyo, which incorporated in 1921 as Motosaburo Tanabe Shoten.
In 1921, Nippon Tar Industries was established.
In 1940, Takeda Kasei Co., Ltd. was established by Chobei Takeda & Co., Ltd. (present-day Takeda Pharmaceutical Company) and Nippon Kasei Chemical Co. Ltd. (present-day Mitsubishi Chemical Corporation) and built its first plant in Higashi-Yoshitomi-mura, Fukuoka Prefecture.
In 1943, Motosaburo Tanabe Shoten, changed its name to Tokyo Tanabe Pharmaceuticals Co., Ltd.
In 1946, Takeda Kasei Co., Ltd. changed its name to Yoshitomi Pharmaceutical Co., Ltd.
In 1949, Yoshitomi Pharmaceutical Co., Ltd. listed on Tokyo and Osaka stock exchanges.
In 1950, The Blood Plasma Corporation of Japan was established with head office and plant in Osaka. The founders included war criminals such as Kitano Masaji who performed torture and experimentations on humans in the Japanese military's notorious Unit 731 during World War II. These crimes were recognized by the UN as extreme "crimes against humanity".
In 1952, Nippon Tar Industries became Mitsubishi Chemical Industries, Ltd.
In 1964, Blood Plasma Corporation changed its name to Green Cross Corporation.
In 1998, Green Cross Corporation was acquired by Yoshitomi Pharmaceutical.
In 2000, Green Cross Corporation changing its name to Welfide Corporation.
In 1981, Mitsubishi Chemical Industries, Ltd. established a business alliance with Tokyo Tanabe Pharmaceuticals Co.
In 1984, Mitsubishi Chemical Industries, Ltd. changed its name to Mitsubishi Chemical Corporation following the merger with Mitsubishi Petrochemical Co., Ltd.
In 1999, Mitsubishi Chemical Corporation and Tokyo Tanabe Pharmaceuticals Co. merged formally and formed Mitsubishi-Tokyo Pharmaceuticals, Inc., to take over the combined pharmaceutical operations of the two companies.
In 2001, Mitsubishi-Tokyo Pharmaceuticals and Welfide Corporation merged to establish Mitsubishi Pharma Corporation, and Mitsubishi Tanabe Pharma.[8]
In October 2005, Mitsubishi Pharma Corporation joined again with Mitsubishi Chemical Corporation to create Mitsubishi Chemical Holdings Corporation.
In July, 2017, Mitsubishi Tanabe Pharma acquired Neuroderm for $1.1 billion.[9]
On 27 February 2020, Mitsubishi Tanabe Pharma was delisted from the Tokyo Stock Exchange, and is now described as a member of the Mitsubishi Chemical Holdings Group [10]